And a regular monitoring of the HER2 status to evaluate the prognosis and reconsider treatment strategies was potentially required, but clinical monitoring of molecular mutations or changes in expression through repeated biopsy of tumor tissues would be difficult, because of its invasive nature, high incidence of inducing tumor metastasize, and so on. Here, ERBB2 is linked to neoplasm.